carboxyphosphamide: metabolite of cyclophosphamide; RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 31515 |
| CHEMBL ID | 3544547 |
| CHEBI ID | 3410 |
| MeSH ID | M0040044 |
| Synonym |
|---|
| asta 5754 |
| brn 2053657 |
| hydracrylic acid, n,n-bis(2-chloroethyl)phosphorodiamidate |
| propanoic acid, 3-((amino(bis(2-chloroethyl)amino)phosphinyl)oxy)- |
| ccris 5126 |
| 2-carboxyethyl-n,n-bis(2-chloroethyl)phosphorodiamidate |
| C07646 |
| carboxycyclophosphamide |
| 22788-18-7 |
| carboxyphosphamide |
| propanoic acid, 3-[[amino[bis(2-chloroethyl)amino]phosphinyl]oxy]- |
| nsc-145124 |
| nsc145124 |
| nsc 145124 |
| o-(2-carboxyethyl) n,n-bis(2-chloroethyl)phosphorodiamidate |
| hydracrylic acid,n-bis(2-chloroethyl)phosphorodiamidate |
| FT-0664360 |
| 3-[amino-[bis(2-chloroethyl)amino]phosphoryl]oxypropanoic acid |
| dp4677ax41 , |
| unii-dp4677ax41 |
| 3-[[amino[bis(2-chloroethyl)amino]phosphinyl]oxy]propanoic acid |
| CHEBI:3410 , |
| cepm |
| propanoic acid, 3-((amino(bis(2-chloroethyl)amino)phosphinyl)oxy)- (9ci) |
| asta-5754 |
| CHEMBL3544547 |
| AKOS027322743 |
| J-014854 |
| 2-carboxyethyl n,n-bis(2-chloroethyl)phosphorodiamidate |
| Q15716203 |
| 3-({amino[bis(2-chloroethyl)amino]phosphoryl}oxy)propanoic acid |
| DTXSID801030866 |
| 3-((amino(bis(2-chloroethyl)amino)phosphoryl)oxy)propanoic acid |
| Class | Description |
|---|---|
| nitrogen mustard | Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
carboxyphosphamide is involved in 5 pathway(s), involving a total of 1733 unique proteins and 1603 unique compounds
| Pathway | Proteins | Compounds |
|---|---|---|
| Metabolism | 1496 | 1108 |
| Biological oxidations | 150 | 276 |
| Phase I - Functionalization of compounds | 69 | 175 |
| Cyclophosphamide Action Pathway | 9 | 22 |
| Cyclophosphamide Metabolism Pathway | 9 | 22 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 6 (46.15) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Article | Year |
|---|---|
| Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy. European journal of cancer (Oxford, England : 1990), Volume: 47, Issue: 10 | 2011 |
| [information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | |